首页> 美国卫生研究院文献>Therapeutics and Clinical Risk Management >Ropinirole in restless legs syndrome and periodic limb movement disorder
【2h】

Ropinirole in restless legs syndrome and periodic limb movement disorder

机译:罗匹尼罗在腿不安综合征和周期性肢体运动障碍中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Restless legs syndrome and periodic limb movement disorder of sleep are now recognized as prevalent, distinct, yet overlapping disorders affecting all age groups. Although delineation of the mechanisms underlying these disorders continues to be the focus of very intense research efforts, it has become apparent that there is a prominent role for dopaminergic agents in the clinical management of these patients. Among the various dopaminergic drugs, ropinirole has undergone relatively intense and critical scrutiny, and appears to provide a safe and efficacious treatment option for patients with these two conditions. The more recent development of a controlled formulation for this drug is likely to yield additional benefits such as improved adherence and reduced fluctuations in daytime and nighttime symptoms. However, there is not enough evidence at this time to support such assumption.
机译:如今,人们普遍认为不安腿综合征和周期性肢体运动障碍是影响所有年龄段的普遍,独特,但重叠的疾病。尽管描述这些疾病的潜在机制仍然是非常激烈的研究工作的重点,但显而易见的是,多巴胺能药物在这些患者的临床治疗中起着重要作用。在各种多巴胺能药物中,罗匹尼罗已经经历了相对激烈和严格的审查,似乎为患有这两种疾病的患者提供了一种安全有效的治疗选择。该药物的可控制剂的最新发展可能会带来额外的好处,例如改善依从性以及减少白天和夜间症状的波动。但是,目前没有足够的证据支持这种假设。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号